


レボセチリジン二塩酸塩 (米国薬局方記載条件)

Levocetirizine Dihydrochloride (The United States Pharmacopeia)

AB191123A

(A) System suitability solution\*


(0.2 mg/mL Levocetirizine dihydrochloride, 0.2 µg/mL Chlorobenzhydryl piperazine, 0.2 µg/mL Cetirizine amide)






	System suitability requirement	Result
Resolution (1, 2)	≥ 3.0	9.0
Tailing factor (Levocetirizine)	≤ 2.0	0.9

(B) Standard solution\*

(0.2 µg/mL Levocetirizine dihydrochloride, 0.2 µg/mL Chlorobenzhydryl piperazine, 0.2 µg/mL Cetirizine amide)



	System suitability requirement	Result
Relative standard deviation of the peak area (Levocetirizine)	≤ 5.0%	3.96%



Column : YMC-Triart SIL (5 µm, 12 nm)  
250 X 4.6 mm I.D.

Eluent : acetonitrile/water/1 M sulfuric acid (93/6.6/0.4)

Flow rate : 1.0 mL/min

Temperature : 30°C

Detection : UV at 230 nm

Injection : 20 µL

(The United States Pharmacopeia 42th; Impurities)

\*All system suitability and standard solutions were prepared from Levocetirizine Dihydrochloride supplied as a reagent for laboratory use.